MAVYRET DEMONSTRATED HIGH CURE* RATES IN 8 WEEKS1
*Cure = sustained virologic response (SVR12); HCV RNA < LLOQ at 12 weeks after the end of treatment.

98
%
CURE* RATE (SVR12)
across 3 studies in GT 1–6 treatment naïve and GT 1, 2, 4–6 PRS-experienced,† non-cirrhotic patients who received 8 weeks of treatment (n=745/763)1
SVR12 range: 93-100% (ITT); 96-100% (mITT)1
mITT=ITT population modified to exclude subjects who did not achieve SVR12 for reasons other than virologic failure
AASLD & IDSA GUIDELINES
MAVYRET is a recommended regimen for 8 weeks in GT 1–6 treatment-naïve, non-cirrhotic patients11
See guidelines for special population recommendations
AASLD is a registered trademark of the American Association for the Study of Liver Diseases and IDSA is a registered trademark of the Infectious Diseases Society of America.
AASLD and IDSA have not endorsed, and are not sponsors of, or otherwise affiliated with, this advertisement by AbbVie Inc. All information subject to change.
†PRS-experienced = prior treatment experience with regimens containing interferon (IFN), pegylated interferon (pegIFN), ribavirin (RBV), and/or sofosbuvir (SOF), but no prior treatment experience with an NS5A inhibitor or HCV NS3/4A protease inhibitor.
- NO ribavirin1
- NO baseline viral load restrictions1
- NO baseline resistance testing required1
- NO dose adjustment for renal impairment1
0.3% on-treatment virologic failure (n=2/763)1
1% relapse (n=7/751)1
SVR12 by GT and SUBGROUP
- ITT
- mITT
- 100
- 80
- 60
- 40
- 20
- 0
- 100
- 80
- 60
- 40
- 20
- 0
Includes GT 1–6 treatment-naïve and GT 1, 2, 4–6 PRS-experienced* non-cirrhotic patients who received 8 weeks of treatment
*PRS-experienced = prior treatment experience with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir, but no prior treatment experience with an HCV NS3/4A PI or NS5A inhibitor.
ITT = intent-to-treat, mITT = modified intent-to-treat.
mITT = ITT population modified to exclude subjects who did not achieve SVR12 for reasons other than virologic failure.
- ITT
- mITT
- 100
- 80
- 60
- 40
- 20
- 0
- 100
- 80
- 60
- 40
- 20
- 0
Post-hoc analysis includes GT 1–6 treatment-naive and GT 1, 2, 4–6 PRS-experienced† non-cirrhotic patients who received 8 weeks of treatment
*Primary Investigator-reported PPI use.
†PRS-experienced = prior treatment experience with regimens containing interferon, pegylated interferon, ribavirin, and/or sofosbuvir, but no prior treatment experience with an HCV NS3/4A PI or NS5A inhibitor.
ITT = intent-to-treat, mITT = modified intent-to-treat.
mITT = ITT population modified to exclude subjects who did not achieve SVR12 for reasons other than virologic failure.
STUDY DESIGNS
MAVYRET FOR 8 OR 12 WEEKS IN GT 1 PATIENTS: Highlights from a clinical trial published in New England Journal of Medicine, 2018.
Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. Zeuzem S, Foster GR, Wang S, et al. N Engl J Med.
2018;378(4):354-369.
SVR12 (ITT) IN 8 WEEKS
- 100
- 80
- 60
- 40
- 20
- 0
Study summary
- Randomized, open-label, multicenter, phase 3 (N=703)
- Once-daily dose of 300-mg glecaprevir and 120-mg pibrentasvir (3 tablets, once daily, with food)
- 8 or 12 weeks of treatment
- Endpoints: SVR12 in the 12-week arm; SVR12 in the 8-week arm vs 12-week arm
8-week patient baseline characteristics (N=351)
- 43% Genotype 1a
- 48% Male
- 18% Non-white race
- 85% F0/F1 fibrosis score
- 28% History of injection drug use
MAVYRET FOR 8 OR 12 WEEKS IN GT 3 PATIENTS: Highlights from a clinical trial published in New England Journal of Medicine, 2018.
Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. Zeuzem S, Foster GR, Wang S, et al. N Engl J Med.
2018;378(4):354-369.
SVR12 (ITT) IN 8 WEEKS
- 100
- 80
- 60
- 40
- 20
- 0
Study summary
- Partially randomized, open-label, active-controlled, multicenter, phase 3 (N=505): 2:1 randomizaton of MAVYRET vs SOF 400 mg + DCV 60 mg for 12 weeks, and nonrandomized MAVYRET for 8 weeks
- Once-daily dose of 300-mg glecaprevir and 120-mg pibrentasvir (3 tablets, once daily, with food)
- 8 or 12 weeks of treatment
- Endpoints: SVR12 in the 8-week arm vs 12-week arm
8-week patient baseline characteristics (N=157)
- 96% Genotype 3a
- 59% Male
- 15% Non-white race
- 78% F0/F1 fibrosis score
- 66% History of injection drug use
A randomized, open-label, multicenter, 4-part, phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of MAVYRET with or without RBV in 691 treatment-naïve or treatment-experienced (ie, IFN or pegIFN ± RBV, or SOF + RBV ± pegIFN) GT 2–6-infected adults, without cirrhosis or with compensated cirrhosis. Part 2: GT 2, 3 non-cirrhotic patients were administered MAVYRET for 8 weeks and GT 3 patients without cirrhosis or with compensated cirrhosis were administered MAVYRET with or without ribavirin for 12 weeks. Part 4: GT 2, 4–6 non-cirrhotic patients were administered MAVYRET for 8 weeks. Primary endpoints: SVR12 in each treatment arm and noninferiority of SVR12 for GT 2 (Part 4) to historical control with 12 weeks of sofosbuvir + ribavirin.
Study population per recommended regimen:
- GT
2, 4-6 - NON-CIRRHOTIC
- TREATMENT-NAÏVE or
PRS-EXPERIENCED - 8 WEEKS
SAFETY PROFILE DEMONSTRATED IN CLINICAL TRIALS

OVERALL DISCONTINUATION RATE OF MAVYRET*
3 out of ~2300 patients discontinued treatment due to adverse reactions1,9
- The most common adverse reactions (≥5% prevalence) were headache (13%), fatigue (11%), and nausea (8%) in patients treated with MAVYRET1
- Most adverse reactions were mild in severity1
- 1 subject experienced a serious adverse reaction1
*Discontinuations in Expedition 2, Expedition 4 and Magellan 2 are not included in the overall rate.